A $31bn Opportunity? Future Of Biosimilars Inches Closer With Samsung Keytruda Study
Kick Off For Samsung Phase I Study Follows Recent Phase III News From Sandoz
Samsung Bioepis is among a small pool of players heading to the clinic for a proposed biosimilar to Merck & Co’s PD-1 mega-blockbuster, as interest and investment rises ahead of patent expiry at the end of the decade.
